These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 29581117)

  • 1. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
    Zykov IN; Samuelsen Ø; Jakobsen L; Småbrekke L; Andersson DI; Sundsfjord A; Frimodt-Møller N
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
    Lepeule R; Ruppé E; Le P; Massias L; Chau F; Nucci A; Lefort A; Fantin B
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1376-81. PubMed ID: 22214774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.
    Fedrigo NH; Mazucheli J; Albiero J; Shinohara DR; Lodi FG; Machado ACDS; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607025
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Lepak AJ; Zhao M; VanScoy B; Taylor DS; Ellis-Grosse E; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
    Deemer K; Grey J; Fronczek C; Marr K
    Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S105-S110. PubMed ID: 32840305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
    Senol S; Tasbakan M; Pullukcu H; Sipahi OR; Sipahi H; Yamazhan T; Arda B; Ulusoy S
    J Chemother; 2010 Oct; 22(5):355-7. PubMed ID: 21123160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.
    VanScoy BD; McCauley J; Ellis-Grosse EJ; Okusanya OO; Bhavnani SM; Forrest A; Ambrose PG
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7170-7. PubMed ID: 26100706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases.
    Bahramian A; Eslami G; Hashemi A; Tabibi A; Heidary M
    Acta Microbiol Immunol Hung; 2018 Mar; 65(1):15-25. PubMed ID: 29137487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
    J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model.
    Zykov IN; Frimodt-Møller N; Småbrekke L; Sundsfjord A; Samuelsen Ø
    Int J Antimicrob Agents; 2020 Feb; 55(2):105851. PubMed ID: 31770624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
    Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
    Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
    Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
    BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.
    Sastry S; Clarke LG; Alrowais H; Querry AM; Shutt KA; Doi Y
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7355-61. PubMed ID: 26369978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Bi W; Li B; Song J; Hong Y; Zhang X; Liu H; Lu H; Zhou T; Cao J
    Int J Antimicrob Agents; 2017 Jul; 50(1):29-34. PubMed ID: 28456703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake.
    Martín-Gutiérrez G; Docobo-Pérez F; Rodriguez-Beltrán J; Rodríguez-Martínez JM; Aznar J; Pascual A; Blázquez J
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum β-lactamase.
    Lefort A; Chau F; Lepeule R; Dubée V; Kitzis MD; Dion S; Fantin B
    Int J Antimicrob Agents; 2014 Apr; 43(4):366-9. PubMed ID: 24388117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Wilson DT; May DB
    Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.